Major breakthrough in Tigenix’ Crohn’s research

Share this article

About one year ago, patients received a single injection of Cx601. Half of the patients were healed after 24 weeks. One year later, 1 in 2 (54%) patients still experiences the positive effect of the drug. This is very good news for TiGenix, because if diseases can be cured with a single injection, the probability increases that the product will be reimbursed by the health insurance. Previous studies already showed that the treatment has a favorable safety profile. Moreover, these results equip TiGenix with extra leverage to go to investors and pharma companies. The biotech company is looking for a pharmaceutical company to fund the last stage of the clinical trial in the US and wants to make an IPO on NASDAQ.